Vertex Pharmaceuticals

Vertex Pharmaceuticals, incorporated in 1989 and headquartered in Boston, Massachusetts, USA, is at the forefront of developing innovative therapies for cystic fibrosis (CF) and other severe, life-limiting diseases. The company has established a strong presence in the pharmaceutical industry with its focus on small molecule drugs. The company's portfolio of products includes several significant brands that have made strides in CF treatment. These brands include Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor), Symdeko/Symkevi (tezacaftor/ivacaftor and ivacaftor), and Trikafta in the United States, which is known as Kaftrio in Europe (elexacaftor/tezacaftor/ivacaftor and ivacaftor). These brands have contributed to the company's reputation as a leader in the field of CF treatment. Vertex Pharmaceuticals' products and services have a significant market presence in the United States. Beyond its home market, the company also serves other regions with advanced healthcare infrastructures, including the European Union, Canada, and Australia. The availability and marketing approval of its drugs vary across different countries, aligning with local regulatory requirements and healthcare practices. (Powered by AI)